Cargando…
Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Sorafenib resistance is one of the major obstacles towards achieving a better outcome in patients with advanced hepatocellular carcinoma (HCC), in which aberrant activation of the hepatocyte growth factor (HGF)/mesenchymal‐epithelial transition pathway is frequently observed. Here, we report that HC...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356182/ https://www.ncbi.nlm.nih.gov/pubmed/30761258 http://dx.doi.org/10.1002/2211-5463.12578 |
_version_ | 1783391470785396736 |
---|---|
author | Chen, Weibo Yang, Junsheng Zhang, Yue Cai, Huihua Chen, Xuemin Sun, Donglin |
author_facet | Chen, Weibo Yang, Junsheng Zhang, Yue Cai, Huihua Chen, Xuemin Sun, Donglin |
author_sort | Chen, Weibo |
collection | PubMed |
description | Sorafenib resistance is one of the major obstacles towards achieving a better outcome in patients with advanced hepatocellular carcinoma (HCC), in which aberrant activation of the hepatocyte growth factor (HGF)/mesenchymal‐epithelial transition pathway is frequently observed. Here, we report that HCC cells develop sorafenib resistance following HGF stimulation. Furthermore, HGF activates the downstream extracellular signal‐related kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) pathway and induces epithelial–mesenchymal transition (EMT) by up‐regulating Snail in HCC cells. Inhibition of ERK and STAT3 abolished the rescue effect of HGF by down‐regulating Snail and EMT. Moreover, phosphoinositide 3‐kinase/Akt was also activated in HGF‐treated HCC cells, although it had no effect on Snail expression. Notably, we also found that regorafenib reversed HGF‐induced sorafenib resistance by inhibiting ERK and STAT3, and subsequently down‐regulating Snail and EMT. Taken together, our results indicate that HGF induces sorafenib resistance by activating phosporylated (P)‐ERK/Snail/EMT and P‐STAT3/Snail/EMT pathways. Inhibition of P‐ERK and P‐STAT3 by regorafenib can block HGF‐induced EMT, thereby reversing HGF‐induced sorafenib resistance. |
format | Online Article Text |
id | pubmed-6356182 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63561822019-02-13 Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma Chen, Weibo Yang, Junsheng Zhang, Yue Cai, Huihua Chen, Xuemin Sun, Donglin FEBS Open Bio Research Articles Sorafenib resistance is one of the major obstacles towards achieving a better outcome in patients with advanced hepatocellular carcinoma (HCC), in which aberrant activation of the hepatocyte growth factor (HGF)/mesenchymal‐epithelial transition pathway is frequently observed. Here, we report that HCC cells develop sorafenib resistance following HGF stimulation. Furthermore, HGF activates the downstream extracellular signal‐related kinase (ERK) and signal transducer and activator of transcription 3 (STAT3) pathway and induces epithelial–mesenchymal transition (EMT) by up‐regulating Snail in HCC cells. Inhibition of ERK and STAT3 abolished the rescue effect of HGF by down‐regulating Snail and EMT. Moreover, phosphoinositide 3‐kinase/Akt was also activated in HGF‐treated HCC cells, although it had no effect on Snail expression. Notably, we also found that regorafenib reversed HGF‐induced sorafenib resistance by inhibiting ERK and STAT3, and subsequently down‐regulating Snail and EMT. Taken together, our results indicate that HGF induces sorafenib resistance by activating phosporylated (P)‐ERK/Snail/EMT and P‐STAT3/Snail/EMT pathways. Inhibition of P‐ERK and P‐STAT3 by regorafenib can block HGF‐induced EMT, thereby reversing HGF‐induced sorafenib resistance. John Wiley and Sons Inc. 2019-01-18 /pmc/articles/PMC6356182/ /pubmed/30761258 http://dx.doi.org/10.1002/2211-5463.12578 Text en © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Chen, Weibo Yang, Junsheng Zhang, Yue Cai, Huihua Chen, Xuemin Sun, Donglin Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
title | Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
title_full | Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
title_fullStr | Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
title_full_unstemmed | Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
title_short | Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
title_sort | regorafenib reverses hgf‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356182/ https://www.ncbi.nlm.nih.gov/pubmed/30761258 http://dx.doi.org/10.1002/2211-5463.12578 |
work_keys_str_mv | AT chenweibo regorafenibreverseshgfinducedsorafenibresistancebyinhibitingepithelialmesenchymaltransitioninhepatocellularcarcinoma AT yangjunsheng regorafenibreverseshgfinducedsorafenibresistancebyinhibitingepithelialmesenchymaltransitioninhepatocellularcarcinoma AT zhangyue regorafenibreverseshgfinducedsorafenibresistancebyinhibitingepithelialmesenchymaltransitioninhepatocellularcarcinoma AT caihuihua regorafenibreverseshgfinducedsorafenibresistancebyinhibitingepithelialmesenchymaltransitioninhepatocellularcarcinoma AT chenxuemin regorafenibreverseshgfinducedsorafenibresistancebyinhibitingepithelialmesenchymaltransitioninhepatocellularcarcinoma AT sundonglin regorafenibreverseshgfinducedsorafenibresistancebyinhibitingepithelialmesenchymaltransitioninhepatocellularcarcinoma |